Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1608 participants.
Also called NCT02316886
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,608 participants
- Registry
-
NCT02316886
-
- Other papers using this trial's data
- Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Japan, New Zealand, South Korea, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT02316886. Randomized; no masking; primary purpose treatment. Start 2015-10-05 (actual); primary completion 2023-10-19 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque
- Acronym
- PREVENT
- Condition
- Coronary Artery Disease
- Condition
- Plaque, Atherosclerotic
- Intervention (Device)
- Coronary intervention
- Intervention (Drug)
- Optimal Medical treatment
- Lead sponsor
- Seung-Jung Park
- Collaborator
- CardioVascular Research Foundation, Korea
Record details
- Record id
cardio:ct-nct02316886- Content hash
50ee2d81691f12973e2105c1630219db0c8b9eb47b38174d9170160b5f679298